摘要
目的:探讨非小细胞肺癌(NSCLC)患者淋巴结微转移MUC1表达用于分子诊断特异性和敏感性及临床意义。方法:应用逆转录聚合酶链反应(RT-PCR)技术,对31例肺癌患者119枚和10例肺良性病变患者35枚淋巴结MUC1mRNA表达进行检测。结果:巢式RT-PCR技术的敏感性达10-6。RT-PCR检测的119枚肺癌患者淋巴结中65枚存在MUC1mRNA表达,阳性率为54.6%(65/119);病理学方法检测出41枚淋巴结存在癌转移,阳性率为34.5%(41/119)。肺良性病变患者35枚淋巴结中MUC1mRNA表达均为阴性。淋巴结微转移与肺癌组织学类型、细胞分化程度及pTNM分期均存在密切关系(P<0.05)。结论:RT-PCR是一种特异性、敏感性均较高的肿瘤微转移检测方法,MUC1mRNA可能是检测肺癌微转移的一个有价值的指标,为制定治疗方案和评估预后提供重要的参考依据。
Objective: To explore the clinical significance and sensitive of molecular diagnosis of detecting micromatastasis in lymph node from non-small cell lung cancer patients Methods: The MUC1 mRNA expression was detected in 119 lymph nodes from 31 lung cancer patients and 35 lymph nodes from 10 benign pulmonary lesion patients by nested RT-PCR. Results: The sensitive of RT-PCR technique was 10-6 in this study. In the 119 lymph nodes from lung cancer patients, MUC1 mRNA expression (54.5%, 65/119) was detected in 65 lymph nodes by RT-PCR. Cancer metastasis (34.5%, 41/119) was observed in 41 lymph modes by HE staining. None of MUC1 mRNA expression was observed in all the 35 lymph nodes in the benign pulmonary lesion groups. The micromatastasis in lymph nodes were closely related to the pathological classification, cell differentiation of the cancer and P-TNM stage of the disease (P<0.05). Conclusion: RT-PCR technique is a specific and sensitive method to detect micromatastasis in patients with lung cancer. MUC1 mRNA might be a valuable marker to detect micromatastasis in lung cancer patients. It can also provide important clinical information for the evaluation of prognosis and in the selection of appropriate treatment strategies.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2004年第18期5-7,23,共4页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金资助(编号:30070333)
关键词
非小细胞肺癌
微转移
粘蛋白1
淋巴结
分子诊断
Non-small cell lung cancer Micromatastasis MUC1 Lymph node Molecular diagnosis
